| Item Type | Name |
|
Concept
|
Calcitonin Gene-Related Peptide
|
|
Concept
|
Receptors, Calcitonin Gene-Related Peptide
|
|
Academic Article
|
Current understanding and treatment of headache disorders: five new things.
|
|
Academic Article
|
Is CGRP a marker for chronic migraine?
|
|
Academic Article
|
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.
|
|
Academic Article
|
TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine. Some like it hot! Chronic migraine increases TRPV1 receptors in the scalp.
|
|
Academic Article
|
Targeting CGRP: A New Era for Migraine Treatment.
|
|
Academic Article
|
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
|
|
Academic Article
|
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
|
|
Academic Article
|
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.
|
|
Academic Article
|
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
|
|
Academic Article
|
Fremanezumab for the Preventive Treatment of Chronic Migraine.
|
|
Academic Article
|
Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.
|
|
Academic Article
|
CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.
|
|
Academic Article
|
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
|
|
Academic Article
|
Erenumab in the treatment of migraine.
|
|
Academic Article
|
From LBR-101 to Fremanezumab for Migraine.
|
|
Academic Article
|
Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic Migraine.
|
|
Academic Article
|
Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials.
|
|
Academic Article
|
Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
|
|
Academic Article
|
Basic Considerations for the Use of Monoclonal Antibodies in Migraine.
|
|
Academic Article
|
Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
|
|
Academic Article
|
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.
|
|
Academic Article
|
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial.
|
|
Academic Article
|
Fremanezumab for the preventive treatment of migraine.
|
|
Academic Article
|
Novel Medications for the Treatment of Migraine.
|
|
Academic Article
|
Preventive Treatment for Episodic Migraine.
|
|
Academic Article
|
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions.
|
|
Academic Article
|
A comprehensive overview and safety evaluation of fremanezumab as a preventive therapy for migraine.
|
|
Academic Article
|
Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
|
|
Academic Article
|
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24?weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study.
|
|
Academic Article
|
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.
|
|
Academic Article
|
Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
|
|
Academic Article
|
The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine.
|
|
Academic Article
|
Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
|
|
Academic Article
|
Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale.
|
|
Academic Article
|
Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System.
|
|
Academic Article
|
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
|
|
Academic Article
|
Developments in targeting calcitonin gene-related peptide.
|
|
Academic Article
|
Emerging target-based paradigms to prevent and treat migraine.
|